AOTXF.US AOTXF
- Market cap
- USD 4.98B
- P/E
- -
- P/B
- 20.18x
- ROE
- -43.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is AOTXF.US undervalued?
Graham numberThe Graham number of AOTXF cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AOTXF fundamental analysis
No fundamental analysis for AOTXF yet.
AOTXF stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AOTXF
Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. Apotex Health Corp. has a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent…
Full company profileAOTXF financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AOTXF annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 2.94B | 3.35B | 3.49B | 3.39B |
| Gross Profit | 1.10B | 1.79B | 1.94B | 1.68B |
| Operating Income | 194M | 766M | 1.04B | 347M |
| EBITDA | 162M | 668M | 912M | 317M |
| Net Income | -147M | 152M | 374M | -153M |
| EPS | -0.63 | 0.65 | 1.61 | -0.67 |
| Balance Sheet | ||||
| Total Assets | 4.04B | 4.85B | 4.54B | 4.86B |
| Total Liabilities | 3.31B | 4.56B | 5.10B | 4.51B |
| Shareholders' Equity | 733M | 291M | -558M | 350M |
| Cash & Short-term Investments | 421M | 78.0M | 57.0M | 259M |
| Cash Flow | ||||
| Operating Cash Flow | 571M | 554M | 641M | 117M |
| Capital Expenditure | 112M | 244M | 182M | 247M |
| Free Cash Flow | 459M | 310M | 459M | -129M |
| Ratios | ||||
| ROE | -20.1% | 52.2% | - | -43.8% |
| ROA | -3.6% | 3.1% | 8.2% | -3.2% |
| Net Profit Margin | -5.0% | 4.5% | 10.7% | -4.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AOTXF dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 296.9%
- Ex-dividend date
- Dec 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | CAD 1.11B | 4.79 | 296.9% |
| 2025 | CAD 164M | 0.71 | 108.1% |
| 2024 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AOTXF
- Insiders 14.34%
- Institutions 57.82%
- Public & others 27.85%
- Shares outstanding 229M
- Free float 228M
AOTXF company profile
- Company name
- AOTXF
- Ticker
- AOTXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 6,000
- Fiscal year end
- March
- Address
- 150 Signet Drive, Toronto, ON, Canada, M9L 1T9
- Phone
- (800) 268-4623
- Website
- apotex.com
About AOTXF
Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. Apotex Health Corp. has a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. The company was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC.
AOTXF management
10- Mr. Jeff WatsonPresident, CEO & Director · born 1964
- Mr. Brian McClellandChief Financial Officer · born 1968
- Mr. Ariel AlonChief Operating Officer · born 1971
- Mr. Francesco TallaricoChief Legal Officer & Global Head of Government Relations · born 1983
- Mr. Barry FishmanChief Corporate Development Officer · born 1957
- Ms. Carina Vassilieva C.C.P., G.R.P., M.B.A.Chief Human Resources Officer · born 1969
- Dr. Kiran Krishnan Ph.D.Senior Vice President of Global Regulatory Affairs · born 1978
- Mr. Martin AresPresident of Canada & Rest of World · born 1967
- Ms. Christine BaederPresident of Apotex USA & LATAM · born 1973
- Dr. Pradeep SanghviExecutive Vice President of Global Research & Development · born 1965